New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio
November 04, 2021 10:00 ET
|
Novartis Pharma AG
New longer-term efficacy and safety data from pivotal Phase III ASCEMBL study for recently US-approved Scemblix® (asciminib) in patients with PH+ CML-CPEarly findings from YTB323 and PHE885 CAR-T cell...
FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia
October 29, 2021 15:46 ET
|
Novartis Pharma AG
Scemblix provides much-needed and long-awaited new option for patients with chronic myeloid leukemia (CML) who suffer with intolerance or inadequate response after at least two previous tyrosine...
Novartis erzielt im dritten Quartal solide Ergebnisse – mit starkem Wachstum bei Innovative Medicines. Das Unternehmen kündigt eine strategische Überprüfung von Sandoz an
October 26, 2021 01:00 ET
|
Novartis Pharma AG
Ad-hoc-Mitteilung gemäss Art. 53 KR Der Nettoumsatz stieg im dritten Quartal um +5% (kWk¹, +6% USD) Die Division Innovative Medicines wuchs um +7% (kWk, +8% USD)Starke Performance der wichtigsten...
Novartis réalise de solides résultats au 3e trimestre, avec une forte croissance d’Innovative Medicines, et annonce un examen stratégique de Sandoz
October 26, 2021 01:00 ET
|
Novartis Pharma AG
Annonce événementielle selon l’art. 53 RC Chiffre d’affaires net du T3 en progression de +5% (tcc¹, +6% USD)Innovative Medicines: hausse de +7% (tcc, +8% USD)Forte performance des moteurs de...
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz
October 26, 2021 01:00 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +5% (cc¹, +6% USD) Innovative Medicines grew +7% (cc, +8% USD)Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx...
Novartis top-line results for CANOPY-1 Phase III study support further evaluation of canakinumab in lung cancer
October 25, 2021 01:15 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR CANOPY-1 Phase III study did not meet its primary endpoints of overall survival (OS) and progression-free survival (PFS) in...
Global Heart Hub and Novartis partner to tackle ASCVD, a global health crisis and world’s #1 killer
October 19, 2021 01:15 ET
|
Novartis Pharma AG
Invisible Nation is a worldwide network of patient organizations committed to driving a decline in cardiovascular (CV) death by effecting systemic change in atherosclerotic cardiovascular disease...
Sandoz Resolves Legacy Federal Government Civil Investigation in the U.S. Regarding Generic Drugs
October 01, 2021 11:52 ET
|
Novartis Pharma AG
Company previously disclosed settlement agreement in principle and fully provisioned for this resolution Basel, October 1, 2021 – Sandoz Inc., the U.S. subsidiary of Sandoz, has...
Novartis presents new Kisqali® data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
September 19, 2021 07:30 ET
|
Novartis Pharma AG
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced...
Novartis announces findings from a real-world study of alpelisib demonstrating clinical benefit in people with PIK3CA-Related Overgrowth Spectrum (PROS)
September 17, 2021 07:30 ET
|
Novartis Pharma AG
PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissuesAt 24 weeks,...